EVALUATING THE EFFICACY OF ALUMINUM PHOSPHATE FORMULATED L2 BASED HUMAN PAPILLOMA VIRUS VACCINE

  • Chozhavel Rajanthan Tm Research Department of Plant Biology and Biotechnology, Loyola College, Chennai-600 034.
  • Lakshmikanth G. Shantha Biotechnics Limited, Ranga Reddy Dist., Medchal-501 401, Telangana, India.
  • Agastian P. Research Department of Plant Biology and Biotechnology, Loyola College, Chennai-600 034.

Abstract

Objective: Human papilloma virus (HPV) caused cervical cancer the second most common cancer among women worldwide and the most common cancer in developing countries like India. Though, currently type specific prophylactic vaccine have been developed, there is a need for cross protective virus neutralizing vaccine. In this study we have tried to show the multi-epitope vaccine and check the final Alum adjuvant formulated vaccine antibody titer.

Methods: Our study was targeted to analyses the in vivo vaccine efficacy of the aluminum adjuvant formulated recombinant multi epitope antigen with two different grades of aluminum phosphate (pH 5.5 & 6.4). Neutralizing antibody titters against the major neutralizing epitope 17-36 aa region of the N-terminal domain.

Results: The results of this study showed that the final aluminium adjuvant recombinant L2 based multi-epitope vaccine produced antibody against 17-36 peptide one of the proven major virus neutralizing epitope.

Conclusion: L2 based multi-epitope recombinant antigen formulated with aluminium adjuvant can be an low cost, broadly protective HPV vaccine.

Keywords: Human papilloma virus L2, Multi-epitope recombinant vaccine, Aluminum adjuvant.

 

References

1. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat
Rev Cancer 2006;6(10):753-63.
2. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines.
Ann Pharmacother 2006;40(7-8):1344-52.
3. Villa LL. Overview of the clinical development and results of a
quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis
2007;11 Suppl 2:S17-25.
4. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus
L1 major capsid protein self-assembles into virus-like particles that are
highly immunogenic. Proc Natl Acad Sci U S A 1992;89(24):12180-4.
5. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck
RE, et al. Immunological analyses of human papillomavirus capsids.
Vaccine 2001;19(13-14):1783-93.
6. Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol
1997;15(2):27583.
7. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading
frame L2 of cottontail rabbit papillomavirus contains antibody-inducing
neutralizing epitopes. Virology 1991;181(2):572-9.
8. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective
immunity to rabbit oral and cutaneous papillomaviruses by
immunization with short peptides of L2, the minor capsid protein.
J Virol 2002;76(19):9798-805.
9. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO.
Effective vaccination against papilloma development by immunization
with L1 or L2 structural protein of cottontail rabbit papillomavirus.
Virology 1992;187(2):612-9.
10. Roden RB, Yutzy WH th, Fallon R, Inglis S, Lowy DR, Schiller JT.
Minor capsid protein of human genital papillomaviruses contains
subdominant, cross-neutralizing epitopes. Virology 2000;270(2):254-7.
11. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD,
Culp TD, et al. Cross-neutralization of cutaneous and mucosal
Papillomavirus types with anti-sera to the amino terminus of L2.
Virology 2005;337(2):365-72.
12. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses
in differentiating epithelia. Microbiol Mol Biol Rev 2004;68(2):362-72.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement
with the Folin phenol reagent. J Biol Chem 1951;193(1):265-75.
14. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M,
et al. Potent anti-HPV immune responses induced by tandem repeats
of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Vaccine 2009;27(13):1949-56.
15. Yamaguchi H, Miyazaki M. Refolding techniques for recovering
biologically active recombinant proteins from inclusion bodies.
Biomolecules 2014;4(1):235-51.
16. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT,
et al. Protection against heterologous human papillomavirus challenge by
a synthetic lipopeptide vaccine containing a broadly cross-neutralizing
epitope of L2. Proc Natl Acad Sci U S A 2008;105(15):5850-5.
17. Conway MJ, Alam S, Christensen ND, Meyers C. Overlapping and
independent structural roles for human papillomavirus type 16 L2
conserved cysteines. Virology 2009;393(2):295-303.
Statistics
161 Views | 264 Downloads
How to Cite
Tm, C. R., L. G., and A. P. “EVALUATING THE EFFICACY OF ALUMINUM PHOSPHATE FORMULATED L2 BASED HUMAN PAPILLOMA VIRUS VACCINE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 5, Sept. 2015, pp. 199-01, https://innovareacademics.in/journals/index.php/ajpcr/article/view/7290.
Section
Original Article(s)